keyword
MENU ▼
Read by QxMD icon Read
search

Telaprevir

keyword
https://www.readbyqxmd.com/read/29904724/ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-in-hcv-genotype-1-infected-patients-who-failed-previous-protease-inhibitor-therapy
#1
Béla Hunyady, Margit Abonyi, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Viktor Jancsik, Gabriella Lengyel, Erzsébet Makkai, Alajos Pár, Zoltán Péter, Margit Pusztay, Pál Ribiczey, László Rókusz, Christoph Sarrazin, Ferenc Schneider, Simone Susser, Ferenc Szalay, István Tornai, Anna Tusnádi, Eszter Újhelyi, Klára Werling, Mihály Makara
Aim of the study: Combination of ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3DDA±RBV) therapy is shown to be effective in HCV genotype 1 (GT1) infected patients. However, sparse data exist in patients who failed previous boceprevir or telaprevir based therapies. Real life efficacy and safety of this combination were evaluated in HCV GT1b infected patients (mostly cirrhotics) with compensated liver disease who failed previous boceprevir or telaprevir based therapies more than a year before...
June 2018: Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29768546/first-wave-protease-inhibitors-for-hepatitis-c-genotype-1-treatment-a-real-life-experience-in-brazilian-patients
#2
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli
INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center...
March 2018: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/29750017/pharmacokinetic-characteristics-of-telaprevir-in-healthy-korean-male-subjects-and-comparisons-with-japanese
#3
Yewon Choi, Seonghae Yoon, Kyoko Matsumoto, Yoshiyasu Ohta, SeungHwan Lee, Kyung-Sang Yu, In-Jin Jang
Introduction: Telaprevir, a reversible selective inhibitor of viral protease and a potential blocker of viral replication, is indicated for the treatment of hepatitis C virus genotype 1 infection. In this study, the pharmacokinetic profile, safety, and tolerability of telaprevir and the effect of food on telaprevir exposure were evaluated in healthy Korean subjects, and compared with data from a previous study in Japanese male subjects. Methods: The single ascending dose study was conducted in 3 dose-based groups (500, 750, and 1,250 mg, six subjects each) in a fasted state...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29694729/treatment-of-hepatitis-c-virus-infection-in-patients-with-mixed-cryoglobulinemic-syndrome-and-cryoglobulinemic-glomerulonephritis
#4
REVIEW
Stephanie M Rutledge, Raymond T Chung, Meghan E Sise
Cryoglobulinemia is a common extrahepatic manifestation of infection with hepatitis C virus (HCV). When signs and symptoms of systemic vasculitis or glomerulonephritis occur in the presence of circulating cryoglobulins, this syndrome is called "mixed cryoglobulinemia syndrome" (MCS). Historically, interferon-based therapies in HCV have been associated with lower rates of viral cure in patients with MCS than in the general HCV-infected population. The advent of direct-acting antiviral therapies have revolutionized the treatment of HCV, dramatically increasing rates of cure...
April 2018: Hemodialysis International
https://www.readbyqxmd.com/read/29572811/teledermatologist-expert-skin-advice-a-unique-model-of-care-for-managing-skin-disorders-and-adverse-drug-reactions-in-hepatitis-c-patients
#5
Samuel Charlston, Gregory Siller
OBJECTIVES: To conduct an audit of teledermatologist expert skin advice, a store and forward tele-dermatological service, to determine its effectiveness and user satisfaction in managing cutaneous adverse drug reactions in patients with hepatitis C, and to demonstrate a unique collaborative model of care for patients receiving specialised drug therapy. METHODS: A retrospective analysis of data on teledermatologist expert skin advice referrals from January 2014 to December 2015 was performed...
March 23, 2018: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/29536805/the-effect-of-the-first-generation-hcv-protease-inhibitors-boceprevir-and-telaprevir-and-the-relation-to-baseline-ns3-resistance-mutations-in-genotype-1-experience-from-a-small-swedish-cohort
#6
Midori Kjellin, Terése Wesslén, Erik Löfblad, Johan Lennerstrand, Anders Lannergård
BACKGROUND: The clinical experience with protease-inhibitor (PI) triple regimen appears disappointing regarding effect, side effects, high work load, and costs. This real-world study evaluates baseline and emerging resistance-associated substitutions (RASs) and their significance for treatment outcome. METHOD: Thirty-six genotype 1a/b patients treated according to Swedish recommendations during 2011-2013 with triple therapy including pegylated interferon and ribavirin in combination with a protease-inhibitor, either boceprevir (BOC) or telaprevir (TVR), were retrospectively evaluated...
March 2018: Upsala Journal of Medical Sciences
https://www.readbyqxmd.com/read/29513836/effectiveness-of-first-wave-protease-inhibitors-in-hepatitis-c-virus-genotype-1-infection-a-multicenter-study-in-brazil
#7
MULTICENTER STUDY
Cirley Maria de Oliveira Lobato, Natalia Balassiano, Elodie Bomfim Hyppolito, Rafaela Liz Pellegrim Sanchez-Lermen, Izabelle Venturini Signorelli, Miguel Yasuo Tomita Nicacio, Alberto Pereira Firmino Filho, Thais Guaraná de Andrade, José Milton de Castro Lima, Talita Amorim de Arruda, Fernanda Schwanz Coutinho, Everton Felipe do Vale Araujo, Ticiana Mota Esmeraldo, Erlon Cortez, Rafaela Lorenzon Aragão Capeli, Melquior Brunno Mateus de Matos, Francisco Sérgio Rangel Pessoa, Hélder Cássio de Oliveira, Érico Antônio Gomes de Arruda, Patrícia Lofêgo Gonçalves, Antônio Haroldo Araújo Filho, Eliane Bordalo Cathalá Esberard, Francisco José Dutra Souto
INTRODUCTION: In 2013, combination therapy using peginterferon, ribavirin, and boceprevir or telaprevir was introduced to treat hepatitis C virus genotype 1 infection in Brazil. The effectiveness of this therapy in four Brazilian regions was evaluated. METHODS: Clinical and virological data were obtained from patients of public health institutions in five cities, including sustained virological response (SVR) and side effects. Patients with advanced fibrosis (F3/4), moderate fibrosis (F2) for > 3 years, or extra-hepatic manifestations were treated according to Ministry of Health protocol...
January 2018: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/29513538/influence-of-polymer-and-drug-loading-on-the-release-profile-and-membrane-transport-of-telaprevir
#8
Laura I Mosquera-Giraldo, Na Li, Venecia R Wilson, Brittany L B Nichols, Kevin J Edgar, Lynne S Taylor
During the dissolution of amorphous solid dispersions (ASDs), various phase transformations can occur, which will ultimately impact the degree of supersaturation. This study employed dissolution and diffusion measurements to compare the performance of various ASD formulations based on the maximum amount of free drug in the solution that was able to permeate through a cellulose-based membrane. Telaprevir (TPV) was used as the model drug compound, and ASDs were prepared with different drug loadings and with four different polymers...
April 2, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29493385/use-of-next-generation-sequencing-in-the-chat-study-acute-hcv-in-hiv-effect-of-baseline-resistance-associated-ns3-variants-on-treatment-failure
#9
Gurmit Kaur Jagjit Singh, Steve Kaye, James C Abbott, Christoph Boesecke, Juergen Rockstroh, Myra O McClure, Mark Nelson
Background The epidemic of acute HCV infection among HIV-infected men who have sex with men (MSM) is ongoing. Transmission of drug-resistant variants (DRVs) after HCV treatment failure could pose a major threat to the effectiveness of future therapies. We determined the baseline prevalence of pre-existing DRVs in the HCV NS3 protease gene and their effects on the addition of telaprevir (TVR) to standard pegylated interferon and ribavirin (PEG-IFN/RBV) for acute HCV infection in individuals enrolled in a multicentre randomized controlled trial (2013 and 2014)...
March 1, 2018: HIV Clinical Trials
https://www.readbyqxmd.com/read/29297305/pharmacophore-anchor-models-of-flaviviral-ns3-proteases-lead-to-drug-repurposing-for-denv-infection
#10
Nikhil Pathak, Mei-Ling Lai, Wen-Yu Chen, Betty-Wu Hsieh, Guann-Yi Yu, Jinn-Moon Yang
BACKGROUND: Viruses of the flaviviridae family are responsible for some of the major infectious viral diseases around the world and there is an urgent need for drug development for these diseases. Most of the virtual screening methods in flaviviral drug discovery suffer from a low hit rate, strain-specific efficacy differences, and susceptibility to resistance. It is because they often fail to capture the key pharmacological features of the target active site critical for protein function inhibition...
December 28, 2017: BMC Bioinformatics
https://www.readbyqxmd.com/read/29221500/analysis-of-naturally-occurring-resistance-associated-variants-to-ns3-4a-protein-inhibitors-ns5a-protein-inhibitors-and-ns5b-polymerase-inhibitors-in-patients-with-chronic-hepatitis-c
#11
Danhui Sun, Mingjia Dai, Shanshan Shen, Chunyang Li, Xuebing Yan
The first NS3/4A hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir were approved in 2011, and both NS5A and NS5B polymerase inhibitors were launched. Recently, direct-acting antivirals (DAAs) have had a major impact on patients infected with HCV. HCV DAAs are highly effective antivirals with fewer side effects. DAAs have been developed for the treatment of HCV infection in combination with PEG-IFN-α/RBV as well as in IFN-free regimens. However, some drug resistance mutations occur when a single oral DAA is used for treatment, which indicates that there is a low-frequency drug resistance mutation in HCV patients before the application of antiviral drugs...
March 21, 2018: Gene Expression
https://www.readbyqxmd.com/read/29169329/micro-costing-analysis-of-guideline-based-treatment-by-direct-acting-agents-the-real-life-case-of-hepatitis-c-management-in-brazil
#12
Hugo Perazzo, Marcelino Jose Jorge, Julio Castro Silva, Alexandre Monken Avellar, Patrícia Santos Silva, Carmen Romero, Valdilea Gonçalves Veloso, Ruben Mujica-Mota, Rob Anderson, Chris Hyde, Rodolfo Castro
BACKGROUND: Eradication of hepatitis C virus (HCV) using direct-acting agents (DAA) has been associated with a financial burden to health authorities worldwide. We aimed to evaluate the guideline-based treatment costs by DAAs from the perspective of the Brazilian Ministry of Health (BMoH). METHODS: The activity based costing method was used to estimate the cost for monitoring/treatment of genotype-1 (GT1) HCV patients by the following strategies: peg-interferon (PEG-IFN)/ribavirin (RBV) for 48 weeks, PEG-IFN/RBV plus boceprevir (BOC) or telaprevir (TEL) for 48 weeks, and sofosbuvir (SOF) plus daclastavir (DCV) or simeprevir (SIM) for 12 weeks...
November 23, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/29167333/authentic-patient-derived-hepatitis-c-virus-infects-and-productively-replicates-in-primary-cd4-and-cd8-t-lymphocytes-in-vitro
#13
Georgia Skardasi, Annie Y Chen, Tomasz I Michalak
Accumulated evidence indicates that immune cells can support replication of hepatitis C virus (HCV) in infected patients and in culture. However, there is a scarcity of data on the degree to which individual immune cell types support HCV propagation and on characteristics of virus assembled. We investigated the ability of authentic, patient-derived HCV to infect in vitro two closely related but functionally distinct immune cell types, CD4+ and CD8+ T lymphocytes, and assessed properties of virus produced by these cells...
November 22, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28931406/validation-of-a-questionnaire-to-monitor-symptoms-in-hiv-infected-patients-during-hepatitis-c-treatment
#14
Edward R Cachay, Craig Ballard, Bradford Colwell, Francesca Torriani, Charles Hicks, Wm Christopher Mathews
BACKGROUND: Clinicians are incorporating patient-reported outcomes in the management of HIV-infected persons co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients during HCV therapy. DESIGN: Five-year retrospective cohort analysis of persons living with HIV (PLWH) treated for HCV. METHODS: The HCV symptom-inventory (HCV-SI) was administered before, during, and after HCV treatment. Discriminant validity was assessed, separately, in mixed model linear regression of HCV-SI T-scores on treatment regimens (pegylated-interferon and ribavirin; pegylated-interferon, ribavirin, and telaprevir; and interferon-free antivirals); and side effect-related premature treatment discontinuation (SE-DC)...
September 20, 2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28904942/a-simple-but-accurate-method-for-evaluating-drug-resistance-in-infectious-hcvcc-system
#15
Jian-Rui Li, Wen-Jing Li, Jun-Jun Cheng, Meng-Hao Huang, Zhou-Yi Wu, Chen-Chen Jiang, Hu Li, Jin-Hua Chen, Xiao-Qin Lv, Biao Dong, Jian-Dong Jiang, Zong-Gen Peng
Use of direct-acting antivirals sometimes causes viral drug resistance, resulting in inefficiency in treated patients in real-world practice. Therefore, how to rapidly and accurately evaluate drug resistance is an urgent problem to be solved for rational use and development of antivirals in the future. Here, we aim to develop a new method by which we can evaluate easily but effectively whether a drug will still be efficient in the future treatment in infectious hepatitis C virus cell culture system. HCV-infected Huh7...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28901852/recent-advancement-of-direct-acting-antiviral-agents-daas-in-hepatitis-c-therapy
#16
REVIEW
Debasis Das, Mayank Pandya
Hepatitis C virus (HCV) infection is a major health problem worldwide. Approximately, 170-200 million individuals are chronically infected worldwide and a quarter of these patients are at increased risk of developing liver cirrhosis, hepatocellular carcinoma and even liver failure. A complete eradication of the virus is one of the most important treatment goals for antiviral research. In 2011, the first-generation protease inhibitors boceprevir (BOC) telaprevir (TVR) were approved by FDA as the direct-acting antiviral agents...
2018: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28856597/chemical-genetics-based-development-of-small-molecules-targeting-hepatitis-c-virus
#17
REVIEW
Guanghai Jin, Jisu Lee, Kyeong Lee
Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. There are currently no vaccines or efficient therapies without side effects, despite today's advanced medical technology. Currently, the common therapy for most patients (i.e. genotype 1) is combination of HCV-specific direct-acting antivirals (DAAs). Up to 2011, the standard of care (SOC) was a combination of peg-IFNα with ribavirin (RBV). After approval of NS3/4A protease inhibitor, SOC was peg-IFNα and RBV with either the first-generation DAAs boceprevir or telaprevir...
September 2017: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/28856278/efficacy-of-hcv-treatment-in-poland-at-the-turn-of-the-interferon-era-the-epiter-study
#18
Robert Flisiak, Joanna Pogorzelska, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon, Ewelina Tuchendler, Grzegorz Madej, Anna Piekarska, Maciej Jabłkowski, Zbigniew Deroń, Włodzimierz Mazur, Marcin Kaczmarczyk, Ewa Janczewska, Arkadiusz Pisula, Jacek Smykał, Krzysztof Nowak, Marek Matukiewicz, Waldemar Halota, Joanna Wernik, Katarzyna Sikorska, Iwona Mozer-Lisewska, Błażej Rozpłochowski, Aleksander Garlicki, Krzysztof Tomasiewicz, Joanna Krzowska-Firych, Barbara Baka-Ćwierz, Wiesław Kryczka, Dorota Zarębska-Michaluk, Iwona Olszok, Anna Boroń-Kaczmarska, Barbara Sobala-Szczygieł, Bronisława Szlauer, Bogumiła Korcz-Ondrzejek, Jerzy Sieklucki, Robert Pleśniak, Agata Ruszała, Barbara Postawa-Kłosińska, Jolanta Citko, Anna Lachowicz-Wawrzyniak, Joanna Musialik, Edyta Jezierska, Witold Dobracki, Beata Dobracka, Jan Hałubiec, Rafał Krygier, Anna Strokowska, Wojciech Chomczyk, Krystyna Witczak-Malinowska
THE AIM OF THE STUDY: Was to analyze the efficacy achieved with regimens available for chronic hepatitis C (CHC) in Poland between 2013 and 2016. MATERIAL AND METHODS: Data were collected from 29 centers and included 6786 patients with available sustained virologic response (SVR) data between 1 January 2013 and 31 March 2016. RESULTS: The sustained virologic response rate for genotypes (G) 1a, 1b, 2, 3 and 4 was 62%, 56%, 92%, 67% and 56% respectively; 71% patients (n = 4832) were treated with pegylated interferon α (Peg-IFNα) and ribavirin (RBV), with SVR rates of 58%, 49%, 92%, 67% and 55% respectively...
December 2016: Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/28856277/efficacy-and-direct-costs-of-chronic-hepatitis-c-treatment-with-first-generation-ns3-4a-protease-inhibitors-in-a-real-life-population
#19
Anna Piekarska, Ewa Koślińska-Berkan, Kamila Wójcik, Anna Skubała, Maciej Jabłkowski, Zbigniew Deroń, Aleksandra Berkan-Kawińska
INTRODUCTION: Recent years have brought a significant advance in chronic hepatitis C (CHC) treatment that includes development of direct acting antivirals (DAA). Two of them, boceprevir (BOC) and telaprevir (TVR), were first approved for treatment of patients infected with CHC genotype 1 in combination with pegylated interferon (P) and ribavirin (R). Our aim was to evaluate the efficacy and direct costs of BOC/PR and TVR/PR in a real life population. MATERIAL AND METHODS: The study included adult patients qualified for the CHC Therapeutic Programme treated with TVR/PR or BOC/PR...
December 2016: Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/28845110/prioritization-for-interferon-free-regimens-and-potential-drug-interactions-of-current-direct-acting-anti-hepatitis-c-agents-in-routine-clinical-practice
#20
Μargarita Papatheodoridi, George N Dalekos, John Goulis, Spilios Manolakopoulos, Christos Triantos, Kalliopi Zachou, Argyro Koukoufiki, Αnastasia Κourikou, Κonstantinos Ζisimopoulos, Christos Τsoulas, George V Papatheodoridis
BACKGROUND: We determined the proportions of patients with chronic hepatitis C (CHC) in association with possible prioritized indications for interferon-free regimens and the use of co-medications with potential drug-drug interactions (DDIs). METHODS: Five hundred consecutive mono-infected CHC patients seen in 2015 at 5 Greek centers were included. Priorities for interferon-free regimens were based on liver disease severity, contraindication(s) for interferon and prior interferon-treatment failure...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
keyword
keyword
6936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"